Holen Sie sich die Stockscreener-App
6.74
4.01%
0.26
Schlusskurs vom Vortag:
$6.48
Offen:
$6.55
24-Stunden-Volumen:
938.02K
Relative Volume:
0.60
Marktkapitalisierung:
$319.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.19M
KGV:
-2.6124
EPS:
-2.58
Netto-Cashflow:
$-37.34M
1W Leistung:
+8.01%
1M Leistung:
+17.12%
6M Leistung:
+11.77%
1J Leistung:
+57.48%
1-Tages-Spanne:
$6.52
$6.83
1-Wochen-Bereich:
$6.145
$6.83
52-Wochen-Spanne:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Vergleichen Sie ABEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.74 | 319.22M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - marketscreener.com
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthca - GuruFocus
Abeona Therapeutics Inc. CEO and CCO to Speak at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Abeona Therapeutics Leadership to Share Latest Company Updates at Major Healthcare Conference - Stock Titan
Trading (ABEO) With Integrated Risk Controls - news.stocktradersdaily.com
Director Cashes In on Abeona Therapeutics Stock! - TipRanks
Insider Sell: Mark Alvino Sells Shares of Abeona Therapeutics In - GuruFocus
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAbeona Therapeutics (NASDAQ:ABEO), Ascentage Pharma Group (NASDAQ:AAPG) - Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire
Dystrophic Epidermolysis Bullosa Market Predicted to See - openPR.com
ABEO: Sells Priority Review Voucher for $155 Million… - MSN
Abeona Therapeutics finally expanding to make cell-based gene therapy - The Business Journals
Abeona Therapeutics Elects New Directors at Meeting - TipRanks
ABEO: Sells Priority Review Voucher for 155 Million - Smartkarma
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
Stifel Nicolaus Issues Pessimistic Forecast for Abeona Therapeutics (NASDAQ:ABEO) Stock Price - Defense World
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy By Investing.com - Investing.com South Africa
Abeona Therapeutics Reports Improved Financial Performance - TipRanks
Insider Selling: Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success - TipRanks
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy - Investing.com Australia
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO St - GuruFocus
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Po - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com Nigeria
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abeona Therapeutics Inc-Aktie (ABEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Chief Executive Officer |
Jun 06 '25 |
Sale |
6.76 |
50,676 |
342,570 |
1,303,761 |
| O'Malley Brendan M. | SVP, General Counsel |
Jun 06 '25 |
Sale |
6.76 |
10,470 |
70,777 |
378,245 |
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):